These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34349063)

  • 41. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
    Kitazawa T; Shima M
    Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bordet JC; Bolbos R; Brevet M; Leissinger C; Dargaud Y
    J Thromb Haemost; 2020 Mar; 18(3):584-592. PubMed ID: 31782901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action.
    Saenko EL; Ananyeva NM; Kouiavskaia DV; Khrenov AV; Anderson JA; Shima M; Qian J; Scott D
    Haemophilia; 2002 Jan; 8(1):1-11. PubMed ID: 11886458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential role of activated factor VIII (FVIIIa) in FVIIa/tissue factor-dependent FXa generation in initiation phase of blood coagulation.
    Furukawa S; Nogami K; Ogiwara K; Shima M
    Int J Hematol; 2019 Apr; 109(4):390-401. PubMed ID: 30756344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies.
    Matsumoto T; Nogami K; Ogiwara K; Shima M
    Thromb Haemost; 2012 Feb; 107(2):288-301. PubMed ID: 22234708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
    Parunov LA; Soshitova NP; Fadeeva OA; Balandina AN; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
    Thromb Res; 2014 Jan; 133(1):112-9. PubMed ID: 24263002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
    Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
    Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.
    Nakajima Y; Oda A; Baatartsogt N; Kashiwakura Y; Ohmori T; Nogami K
    Blood Adv; 2024 Aug; 8(15):3929-3940. PubMed ID: 38820442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
    Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis.
    Cadé M; Muñoz-Garcia J; Babuty A; Fouassier M; Heymann MF; Monahan PE; Heymann D
    Drug Discov Today; 2022 Jan; 27(1):102-116. PubMed ID: 34311113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 55. Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.
    Hatayama Y; Motokura T; Hosoda Y; Suzuki S; Namba H; Kato K; Kojima N; Horie T; Iwamoto T; Yamashita N; Ichikawa H; Fukuda T
    Clin Appl Thromb Hemost; 2022; 28():10760296221082992. PubMed ID: 35225012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.
    Yada K; Nogami K; Ogiwara K; Shima M
    J Thromb Haemost; 2013 May; 11(5):902-10. PubMed ID: 23517528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
    Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
    Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New therapies using nonfactor products for patients with hemophilia and inhibitors.
    Nogami K; Shima M
    Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.